$VBLT,,,keep an eye out on this. Seeing Alpha Just

Message Board

Previous

| Next

Post# of 23078

(Total Views: 232)

Posted On: 05/25/2017 3:21:52 PM

Posted By: OldSaltDawg

$VBLT,,,keep an eye out on this. Seeing Alpha Just ssued a positive report on this. It is a good read and highlights the companies Phase III trials. Current price is $5.65, down $.10 today. Definitely worth keeping an eye on. I may pick up a block to hold for a little while.

Here is another report I found:

Discussion stirs around Vascular Biogenics Ltd (NASDAQ:VBLT) this week; here is what analysts are saying.
May 23, 2017 - By Migdalia James

Discussion stirs around Vascular Biogenics Ltd (NASDAQ:VBLT) this week; here is what analysts are saying.

Vascular Biogenics Ltd (NASDAQ:VBLT) Ratings Coverage
Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vascular Biogenics had 9 analyst reports since August 24, 2015 according to SRatingsIntel. The firm earned “Mkt Outperform” rating on Monday, September 21 by JMP Securities. The rating was initiated by Chardan Capital Markets on Monday, September 21 with “Buy”. The firm has “Overweight” rating given on Monday, November 9 by Piper Jaffray. H.C. Wainwright initiated Vascular Biogenics Ltd (NASDAQ:VBLT) rating on Tuesday, June 28. H.C. Wainwright has “Buy” rating and $11 target. The company was maintained on Wednesday, March 9 by JMP Securities. The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) earned “Buy” rating by H.C. Wainwright on Tuesday, March 28. On Monday, September 28 the stock rating was maintained by Roth Capital with “Buy”. The stock has “Buy” rating by Roth Capital on Monday, August 24. The firm earned “Buy” rating on Friday, October 23 by Chardan Capital Markets. Below is a list of Vascular Biogenics Ltd (NASDAQ:VBLT) latest ratings and price target changes.

28/03/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.00 Maintain

It is down 78.91% since May 23, 2016 and is uptrending. It has outperformed by 62.21% the S&P500.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The company has market cap of $167.22 million. The Firm is focused on the discovery, development and commercialization of treatments for cancer. It currently has negative earnings. The Company’s program is based on its Vascular Targeting System platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

More notable recent Vascular Biogenics Ltd (NASDAQ:VBLT) news were published by: Globenewswire.com which released: “Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering …” on November 03, 2015, also Marketwatch.com with their article: “5.90” published on October 02, 2014, Quotes.Wsj.com published: “News Vascular Biogenics Ltd.VBLT” on October 01, 2014. More interesting news about Vascular Biogenics Ltd (NASDAQ:VBLT) were released by: Schaeffersresearch.com and their article: “80% Explosion Has Vascular Biogenics Ltd (VBLT) Option Bulls Going Wild” published on June 06, 2016 as well as Seekingalpha.com‘s news article titled: “Vascular Biogenics’ (VBLT) CEO Dror Harats on Q2 2016 Results – Earnings Call …” with publication date: August 15, 2016.